This article has been updated from an earlier version with additional information about the design and size of the WARFARIN trial. Additionally, Iverson has further clarified the difference between its study and the COAG trial.
NEW YORK (GenomeWeb News) – Iverson Genetic Diagnostics said today it has received global exclusive rights from Johns Hopkins University School of Medicine to commercialize a molecular diagnostic test.
Columbia University of New York has received US Patent No. 8,133,492, "Pneumococcus polysaccharide-related vaccines." Nitrocellulose-based or hydrogel-based microarrays and methods of making them are claimed.
Iverson Genetic Diagnostics said this week that the Franciscan Health System in Tacoma, Wash., has begun enrolling patients for the WARFARIN (Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation) study that the company is leading in an effor
While past studies that have attempted to gauge the clinical utility of warfarin PGx testing have been hampered by slow test turnaround times, Iverson is promising to provide genetic test results within 24 hours.
GenMark said that its PCR-based eSensor warfarin sensitivity test panel and XT-8 platform have been selected for use in a clinical trial to assess the impact of genotype on the occurrence of adverse events during warfarin drug therapy.
The CMS approval "is for a clinical study under 'coverage with evidence development' and will cover pharmacogenetic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness," Iverson Genetics said in a statement.